References
- HalletJLawCHLCukierMSaskinRLiuNSinghSExploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomesCancer2015121458959725312765
- HalperinDMShenCDasariAFrequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based studyLancet Oncol201718452553428238592
- GershonMDTackJThe serotonin signaling system: from basic understanding to drug development for functional GI disordersGastroenterology2007132139741417241888
- Grozinsky-GlasbergSGrossmanABGrossDJCarcinoid heart disease: from pathophysiology to treatment – ‘something in the way it moves’Neuroendocrinology2015101426327325871411
- SinghSGranbergDWolinEPatient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETsJ Glob Oncol201631435328717741
- BeaumontJLCellaDPhanATChoiSLiuZYaoJCComparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US populationPancreas201241346146622422138
- HoflandLJLambertsSWJThe pathophysiological consequences of somatostatin receptor internalization and resistanceEndocr Rev2003241284712588807
- FitzpatrickPFTetrahydropterin-dependent amino acid hydroxylasesAnnu Rev Biochem19996835538110872454
- GhiaJ-ELiNWangHSerotonin has a key role in pathogenesis of experimental colitisGastroenterology200913751649166019706294
- WaltherDJPeterJ-UBashammakhSSynthesis of serotonin by a second tryptophan hydroxylase isoformScience200329956037612511643
- LiZChalazonitisAHuangY-YEssential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neuronsJ Neurosci201131248998900921677183
- SavelievaKVZhaoSPogorelovVMGenetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressantsPLoS One2008310e330118923670
- Telotristat ethyl [prescribing information] Available from: https://www.xermelo.com/Media/Default/pdfs/Product_Info_telotristat_ethyl.pdfAccessed October 16, 2017
- MargolisKGStevanovicKLiZPharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestineGut201463692893723749550
- KimJJWangHTercJDZambrowiczBYangQMKhanWIBlocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammationAm J Physiol Gastrointest Liver Physiol20153096G455G46526206858
- KulkeMHO’DorisioTPhanATelotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diar-rhea not adequately controlled by octreotideEndocr Relat Cancer201421570571425012985
- PavelMHörschDCaplinMTelotristat etiprate for carcinoid syndrome: a single-arm, multicenter trialJ Clin Endocrinol Metab201510041511151925636046
- KulkeMHHörschDCaplinMETelotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndromeJ Clin Oncol2017351142327918724
- PavelMGrossDBenaventMEfficacy and safety results of telotristat ethyl in patients with carcinoid syndrome during the double-blind treatment period of the TELECAST stage 3 clinical trialPancreas2017463434
- EllisLMBernsteinDSVoestEEAmerican Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomesJ Clin Oncol201432121277128024638016
- Hannah-ShmouniFStratakisCAKochCAFlushing in (neuro) endocrinologyRev Endocr Metab Disord201617337338027873108
- StrosbergJEl-HaddadGWolinEPhase 3 Trial of 177 Lu-Dotatate for Midgut neuroendocrine tumorsN Engl J Med2017376212513528076709
- PavelMEHainsworthJDBaudinEEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet201137898082005201222119496